Profile
ATNX ZTS TAK HLN TEVA ITCI
Company Name Athenex, Inc. Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Intra-Cellular Therapies, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $2.33M $73.21B $48.16B $45.90B $17.02B $14.00B
Employees 0.27K 13.80K 49.28K 24.56K 33.89K 0.86K
CEO Dr. Yiu-Nam Lau F.R.C.P., M.B.B.S., M.D., Ph.D. Ms. Kristin C. Peck Mr. Christophe Weber Mr. Brian James McNamara Mr. Richard D. Francis Dr. Sharon Mates Ph.D.
Ratings
Trading
ATNX ZTS TAK HLN TEVA ITCI
Last Close $0.2031 $159.61 $15.19 $10.45 $14.85 $131.87
High 52 $0.2 $196.48 $15.19 $10.69 $22.77 $131.91
Low 52 $0.2 $145.54 $12.6 $8.01 $12.78 $64.76
Price vs. 52 Week High 1.55 % -18.77 % 0 % -2.25 % -34.78 % -0.03 %
Price vs. 52 Week Low 1.55 % 9.67 % 20.56 % 30.46 % 16.2 % 103.63 %
Total Return
ATNX ZTS TAK HLN TEVA ITCI
1 Month Return 0 % -6.06 % 2.29 % -2.06 % -5.35 % 0.48 %
3 Month Return 0 % -2.27 % 14.56 % 10.47 % -30.08 % 57.51 %
6 Month Return 0 % -16.01 % 5.27 % 0.77 % -15.09 % 80.92 %
9 Month Return 0 % -9.52 % 16.18 % 23.52 % -11.32 % 90.92 %
YTD Return 0 % -2.04 % 14.73 % 9.54 % -32.62 % 57.89 %
1 Year Return 0 % -3.57 % 12.69 % 26.97 % 6.6 % 96.21 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ATNX ZTS TAK HLN TEVA ITCI
Dividend Yield Percentage (TTM) - 1.1 % 4.23 % 0.01 % - -
Dividend Paid and Capex Coverage Ration (TTM) -36.41 % 2.05 % 1.76 % - 2.5 % -227.26 %
Dividend Per Share (TTM) - 1.8 % 192 % 0.02 % - -
Payout Ratio (TTM) - 31.62 % 145.09 % - - -
Profitability
ATNX ZTS TAK HLN TEVA ITCI
Gross Profit Margin TTM 25.97 % 69.85 % 54.74 % 61.52 % 48.74 % 91.63 %
Return on Assets TTM -48.5 % 17.46 % 1.38 % 4.2 % -4.17 % -5.46 %
Return on Equity TTM 21.51 % 49.65 % 2.83 % 8.73 % -26.15 % -7.4 %
Return on Capital Employed TTM -78.42 % 24.27 % 3.62 % 7.74 % -1.14 % -10.05 %
Net Income Per EBT TTM 100.35 % 79.35 % 89.75 % 75.5 % 127.75 % 100.64 %
EBT Per Ebit TTM 141.03 % 119.26 % 49.18 % 86.58 % 423.43 % 63.57 %
EBIT Per Revenue TTM -68.02 % 28.38 % 10.3 % 19.64 % -1.83 % -17.15 %
Cash Flow To Debt Ratio TTM -177.1 % 43.79 % 22.2 % - 6.9 % -430.93 %
Receivables Turnover TTM 3.69 7.03 6.23 - 5.41 4.09
Payables Turnover TTM 2.26 6.45 4.5 2.19 3.85 2.18
Inventory Turnover TTM 1.78 1.21 1.66 3.63 2.82 2.17
Fixed Asset Turnover TTM 1701.49 % 256.4 % 226.93 % 584.75 % 334.34 % 4569.25 %
Asset Turnover TTM 50.39 % 65.01 % 30.31 % 32.73 % 42.07 % 49.79 %
Operating Cash Flow Per Share TTM -11.47 6.5 678.77 - 1.1 -0.71
Free Cash Flow Per Share TTM -11.78 5.06 484.07 - 0.66 -0.71
Cash Per Share TTM 560.93 % 437.03 % 33271.95 % 24.05 % 291.26 % 970.67 %
Operating Cash Flow Sales Ratio TTM -72.96 % 31.9 % 23.47 % - 7.54 % -10.75 %
Free Cash Flow Operating Cash Flow Ratio TTM 102.75 % 77.82 % 71.32 % - 60.06 % 100.44 %
Cash Flow Coverage Ratios TTM -177.1 % 43.79 % 22.2 % - 6.9 % -430.93 %
Price To Free Cash Flows Ratio TTM -0.03 31.86 9.39 - 22.99 -190.53
Price To Operating Cash Flows Ratio TTM -0.02 25.15 6.69 - 13.65 -185.61
Price Cash Flow Ratio TTM -0.02 25.15 6.69 - 13.65 -185.61
Income Statement (TTM)
ATNX ZTS TAK HLN TEVA ITCI
Revenue $0.1B $9.26B $4263.76B $11.23B $16.54B $0.68B
Gross Profit $0.03B $6.54B $2832.26B $6.95B $8.06B $0.62B
Gross Profit Ratio 25.97% 70.62% 66.4% 61.85% 48.74% 91.63%
EBITDA $-0.07B $3.86B $874.6B $2.51B $-0.3B $-0.12B
Net Income $-0.1B $2.49B $144.07B $1.44B $-1.64B $-0.07B
EPS Diluted -15.13 5.47 91.16 0.16 -1.45 -0.72
Balance Sheet (MRQ)
ATNX ZTS TAK HLN TEVA ITCI
Long Term Debt $0B $5.39B $5029.93B $8.71B $16.3B $0.01B
Total Liabilities $0.2B $9.47B $7834.79B $18.09B $33.61B $0.22B
Total Equity $-0.02B $4.77B $7274.01B $16.22B $5.72B $1.15B
Total Investments $0B $0B $445.7B $0.08B $0B $0.69B
Total Debt $0.04B $6.74B $4843.75B $10.29B $18.08B $0.02B
Total Assets $0.2B $14.24B $15108.79B $34.32B $39.33B $1.37B
Cash Flow Statement (TTM)
ATNX ZTS TAK HLN TEVA ITCI
Net Income $-0.1B $2.5B $144.07B $1.44B $-1.96B $-0.07B
Inventory $-0.02B $-0.04B $-115.74B $0.22B $0.17B $-0.01B
Dividends Paid $0B $-0.79B $-287.19B $-0.57B $0B $0B
Operating Cash Flow $-0.08B $2.95B $716.34B $2.3B $1.25B $-0.07B
Capital Expenditure $-0B $-0.66B $-480.73B $-0.25B $-0.5B $-0B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.29
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.33
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 9.27
ALVOW Alvotech 1.36
AMPH Amphastar Pharmaceuticals, Inc. 27.24
AMRX Amneal Pharmaceuticals, Inc. 7.81
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 68.29
AQST Aquestive Therapeutics, Inc. 2.87
ASRT Assertio Holdings, Inc. 0.683
AVDL Avadel Pharmaceuticals plc 7.2
AYTU Aytu BioPharma, Inc. 1.07
BDSI BioDelivery Sciences International, Inc. 5.59
ETFs With Exposure to ATNX
Ticker ETF Name Weight Percentage Price
IBB iShares Biotechnology ETF 0 123.79
ITOT iShares Core S&P Total U.S. Stock Market ETF 0.00001 117.1
BIB ProShares Ultra Nasdaq Biotechnology 0 45.53
IEIH iShares Evolved U.S. Innovative Healthcare ETF 0 34.1348
DFAU Dimensional US Core Equity Market ETF 0 36.87
IBBQ Invesco Nasdaq Biotechnology ETF 0 20.59
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) 0 6.01125
VEXPX Vanguard Explorer Fd 0 99.84
JKK iShares Morningstar Small-Cap Growth ETF 0.01 307.42
JKJ iShares Morningstar Small-Cap ETF 0 231.193
Unlock